Spectrum Pharmaceuticals Inc. (SPPI)

8.95
NASDAQ : Health Technology
Prev Close 9.45
Day Low/High 8.83 / 9.55
52 Wk Low/High 6.22 / 21.80
Avg Volume 752.60K
Exchange NASDAQ
Shares Outstanding 104.06M
Market Cap 983.32M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Interesting SPPI Put And Call Options For October 18th

Interesting SPPI Put And Call Options For October 18th

Investors in Spectrum Pharmaceuticals Inc saw new options begin trading this week, for the October 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new October 18th contracts and identified one put and one call contract of particular interest.

Spectrum Pharmaceuticals To Present At Two Upcoming Investor Conferences In September

Spectrum Pharmaceuticals To Present At Two Upcoming Investor Conferences In September

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at two upcoming...

Spectrum Pharmaceuticals Reports Second Quarter 2019 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports Second Quarter 2019 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended June 30, 2019.

Spectrum Pharmaceuticals Announces Second Quarter 2019 Financial Results Conference Call

Spectrum Pharmaceuticals Announces Second Quarter 2019 Financial Results Conference Call

Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the second quarter 2019 financial results, provide an update on the company's business, and discuss expectations for the future on...

Noteworthy Friday Option Activity: SPPI, WDAY, S

Noteworthy Friday Option Activity: SPPI, WDAY, S

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Spectrum Pharmaceuticals Inc , where a total volume of 3,141 contracts has been traded thus far today, a contract volume which is representative of approximately 314,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 43.1% of SPPI's average daily trading volume over the past month, of 728,925 shares.

Spectrum Announces Expansion Of The Poziotinib Clinical Program

Spectrum Announces Expansion Of The Poziotinib Clinical Program

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that it is further expanding its poziotinib clinical program by adding three new cohorts in its cornerstone...

Interesting SPPI Put And Call Options For February 2020

Interesting SPPI Put And Call Options For February 2020

Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the February 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Spectrum Pharmaceuticals Appoints Elizabeth Czerepak To Its Board Of Directors

Spectrum Pharmaceuticals Appoints Elizabeth Czerepak To Its Board Of Directors

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the appointment of Elizabeth Czerepak to the Board of Directors.

Spectrum Pharmaceuticals Announces Integrated Results From Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented At The ASCO Annual Meeting

Spectrum Pharmaceuticals Announces Integrated Results From Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented At The ASCO Annual Meeting

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with a primary focus in hematology and oncology, today announced integrated analysis results from two Phase 3 clinical trials of ROLONTIS.

Interesting SPPI Put And Call Options For July 19th

Interesting SPPI Put And Call Options For July 19th

Investors in Spectrum Pharmaceuticals Inc saw new options begin trading this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new July 19th contracts and identified one put and one call contract of particular interest.

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2019 Global Healthcare Conference On June 5th

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2019 Global Healthcare Conference On June 5th

Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Jefferies 2019 Global Healthcare Conference being held in New York.

Spectrum Announces Poziotinib ZENITH20 Trial HER2 Cohort (Cohort 2) Has Reached Enrollment Target

Spectrum Announces Poziotinib ZENITH20 Trial HER2 Cohort (Cohort 2) Has Reached Enrollment Target

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the full enrollment of cohort 2 (N = 87) for previously treated non-small cell lung cancer (NSCLC) patients...

Relative Strength Alert For Spectrum Pharmaceuticals

Relative Strength Alert For Spectrum Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Spectrum Pharmaceuticals To Present Corporate Update At The 20th Annual B. Riley FBR Investor Conference On May 23rd

Spectrum Pharmaceuticals To Present Corporate Update At The 20th Annual B. Riley FBR Investor Conference On May 23rd

Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the 20th Annual B.

Spectrum Pharmaceuticals Reports First Quarter 2019 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports First Quarter 2019 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2019.

Spectrum Announces Asset Purchase And License For A Novel Immuno-Oncology Platform Including Two Early Stage Assets

Spectrum Announces Asset Purchase And License For A Novel Immuno-Oncology Platform Including Two Early Stage Assets

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the closure of an asset purchase and license agreement with ImmunGene, Inc.

Spectrum Pharmaceuticals Announces First Quarter 2019 Financial Results Conference Call

Spectrum Pharmaceuticals Announces First Quarter 2019 Financial Results Conference Call

Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the first quarter 2019 financial results, provide an update on the company's business, and discuss expectations for the future on...

Spectrum Pharmaceuticals To Present Corporate Update At The H.C. Wainwright Global Life Sciences Conference On April 9

Spectrum Pharmaceuticals To Present Corporate Update At The H.C. Wainwright Global Life Sciences Conference On April 9

Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today that an overview of the company's business strategy and development-stage programs will be given at the H.

Spectrum Pharmaceuticals Provides BLA Filing Update For ROLONTIS® (eflapegrastim)

Spectrum Pharmaceuticals Provides BLA Filing Update For ROLONTIS® (eflapegrastim)

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI) announced today that due to the U.

Spectrum Pharmaceuticals To Present Corporate Update At The Oppenheimer 29th Annual Healthcare Conference On March 20

Spectrum Pharmaceuticals To Present Corporate Update At The Oppenheimer 29th Annual Healthcare Conference On March 20

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the Oppenheimer 29...

First Week Of SPPI March 15th Options Trading

First Week Of SPPI March 15th Options Trading

Investors in Spectrum Pharmaceuticals Inc saw new options begin trading this week, for the March 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new March 15th contracts and identified the following call contract of particular interest.

Spectrum Pharmaceuticals Announces The Completion Of The Sale Of Its Marketed Portfolio

Spectrum Pharmaceuticals Announces The Completion Of The Sale Of Its Marketed Portfolio

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today completed the sale of its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.

Spectrum Pharmaceuticals Reports Fourth Quarter 2018 And Full Year 2018 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports Fourth Quarter 2018 And Full Year 2018 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and year ended December 31, 2018.

Spectrum Pharmaceuticals Announces Fourth Quarter And Full Year 2018 Financial Results Conference Call

Spectrum Pharmaceuticals Announces Fourth Quarter And Full Year 2018 Financial Results Conference Call

Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the fourth quarter and full year 2018 financial results, provide an update on the company's business, and discuss expectations for the...

Spectrum Pharmaceuticals To Present Corporate Update At The Guggenheim Healthcare Talks Idea Forum On February 14

Spectrum Pharmaceuticals To Present Corporate Update At The Guggenheim Healthcare Talks Idea Forum On February 14

Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Guggenheim Healthcare Talks Idea Forum | Oncology Day being held in New York.

Spectrum Pharma Sells Marketed Portfolio in a Deal That Could Reach $300 Million

Spectrum Pharma Sells Marketed Portfolio in a Deal That Could Reach $300 Million

Spectrum sells its marketed portfolio of seven FDA-approved products to Acrotech Bio for $160 million up front with a potential for $140 million more in regulatory and sales-based milestones.

Spectrum Pharmaceuticals Sells Marketed Portfolio To Acrotech Biopharma L.L.C. To Focus On New And Innovative Therapies For Cancer Patients

Spectrum Pharmaceuticals Sells Marketed Portfolio To Acrotech Biopharma L.L.C. To Focus On New And Innovative Therapies For Cancer Patients

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI) announced today that it has entered into a definitive agreement to sell its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.

Spectrum Pharmaceuticals Announces Full Enrollment Of The Poziotinib EGFR Cohort For Previously Treated Non-Small Cell Lung Cancer Patients With Exon 20 Insertion Mutations

Spectrum Pharmaceuticals Announces Full Enrollment Of The Poziotinib EGFR Cohort For Previously Treated Non-Small Cell Lung Cancer Patients With Exon 20 Insertion Mutations

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced full enrollment of cohort 1 (N=87) for previously...

TheStreet Quant Rating: D (Sell)